Procept BioRobotics posts investor presentation outlining Aquablation growth strategy in BPH market

PROCEPT BioRobotics Corp.

PROCEPT BioRobotics Corp.

PRCT

0.00
  • Procept outlined a strategy to shift Aquablation from an established option to a leading surgical treatment for BPH.
  • Management sized the U.S. BPH opportunity at about 40 million men, with roughly 400,000 surgical procedures annually.
  • Aquablation penetration estimated at about 10% of the surgical market.
  • Install base growth supported more than 125,000 patients treated worldwide.
  • Category I reimbursement cited as in place as of Jan. 1, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.